Early phase CRO Hammersmith Medicines Research is a leading early-phase CRO with extensive experience in Phase 1 and early Phase 2 studies, signaling a strong potential partner for sponsors needing rapid recruitment, specialized units, and comprehensive early clinical trial services.

Extensive facilities With a large 5,995 m² campus, 145 beds, a sleep unit, laboratories, a pharmacy including aseptic and radiopharmacy capabilities, and volunteer-facing infrastructure, HMR offers end-to-end trial capacity that can support diverse early-stage trials and complex dosing regimens.

Global reach Having earned recognition as one of Europe’s largest early-phase CROs and multiple international trade awards, HMR demonstrates strong export activity and potential for multinational study execution and regulatory navigation.

Innovative tech stack Utilizing iCIMS, AWS, Salesforce, Adobe Experience Cloud and other modern platforms suggests strong digital capabilities for trial recruitment, data management, and sponsor communications, enabling scalable outreach and study administration.

Strategic partnerships Past collaborations and press on acquisitions and partnerships indicate openness to alliance opportunities, joint ventures, or capability expansions with biotech firms, contract manufacturers, and academic institutions to accelerate early-stage programs.